Palo Alto Investors’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-6,774,541
| Closed | -$9.96M | – | 34 |
|
|
2022
Q2 | $9.96M | Hold |
6,774,541
| – | – | 0.87% | 19 |
|
|
2022
Q1 | $7.79M | Buy |
6,774,541
+1,289,328
| +24% | +$2.1M | 0.6% | 23 |
|
|
2021
Q4 | $13.7M | Sell |
5,485,213
-1,371,300
| -20% | -$5.39M | 0.88% | 20 |
|
|
2021
Q3 | $35.1M | Hold |
6,856,513
| – | – | 2.12% | 14 |
|
|
2021
Q2 | $57M | Hold |
6,856,513
| – | – | 3.14% | 13 |
|
|
2021
Q1 | $59.7M | Buy |
6,856,513
+117,600
| +2% | +$1.22M | 3.4% | 11 |
|
|
2020
Q4 | $73.2M | Buy |
6,738,913
+335,313
| +5% | +$4.14M | 3.84% | 11 |
|
|
2020
Q3 | $76.4M | Buy |
6,403,600
+889,924
| +16% | +$11.9M | 4.19% | 8 |
|
|
2020
Q2 | $88.5M | Sell |
5,513,676
-38,127
| -0.7% | -$666K | 5.32% | 8 |
|
|
2020
Q1 | $86.1M | Sell |
5,551,803
-594,142
| -10% | -$12.8M | 7.21% | 4 |
|
|
2019
Q4 | $151M | Sell |
6,145,945
-208,714
| -3% | -$3.1M | 8.32% | 3 |
|
|
2019
Q3 | $65.5M | Sell |
6,354,659
-580,415
| -8% | -$7.32M | 4.37% | 11 |
|
|
2019
Q2 | $87M | Hold |
6,935,074
| – | – | 4.23% | 10 |
|
|
2019
Q1 | $85.9M | Hold |
6,935,074
| – | – | 3.58% | 13 |
|
|
2018
Q4 | $42.7M | Buy |
6,935,074
+28,916
| +0.4% | +$221K | 2.27% | 15 |
|
|
2018
Q3 | $73.2M | Hold |
6,906,158
| – | – | 2.96% | 14 |
|
|
2018
Q2 | $93.6M | Buy |
6,906,158
+11,083
| +0.2% | +$172K | 3.74% | 11 |
|
|
2018
Q1 | $122M | Buy |
6,895,075
+34,232
| +0.5% | +$578K | 5.23% | 8 |
|
|
2017
Q4 | $86.1M | Buy |
6,860,843
+462,547
| +7% | +$6.72M | 3.71% | 9 |
|
|
2017
Q3 | $122M | Buy |
6,398,296
+700,000
| +12% | +$10.7M | 5.13% | 7 |
|
|
2017
Q2 | $86M | Buy |
5,698,296
+907,245
| +19% | +$13.7M | 4.02% | 7 |
|
|
2017
Q1 | $82.2M | Buy |
4,791,051
+1,755,255
| +58% | +$23.4M | 3.88% | 8 |
|
|
2016
Q4 | $36.7M | Buy |
3,035,796
+221,256
| +8% | +$2.31M | 2.1% | 15 |
|
|
2016
Q3 | $27.7M | Buy |
2,814,540
+103,159
| +4% | +$942K | 1.61% | 20 |
|
|
2016
Q2 | $27.8M | Buy |
2,711,381
+55,902
| +2% | +$623K | 2.1% | 13 |
|
|
2016
Q1 | $32.2M | Sell |
2,655,479
-5,500
| -0.2% | -$55.6K | 2.5% | 10 |
|
|
2015
Q4 | $42.6M | Buy |
2,660,979
+545,341
| +26% | +$8.08M | 2.37% | 11 |
|
|
2015
Q3 | $27.2M | Buy |
2,115,638
+2,054,373
| +3,353% | +$41.5M | 1.31% | 17 |
|
|
2015
Q2 | $1.47M | Buy |
+61,265
| New | +$1.18M | 0.07% | 40 |
|
Other funds holding EPZM
Palo Alto Investors's EPZM Position: Q3 2022 in Review
Palo Alto Investors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 6,774,541 shares — an estimated $9.96M sold.
Palo Alto Investors first reported a position in EPZM in Q2 2015 and held it in 29 quarters. The position peaked at $151M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Palo Alto Investors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Palo Alto Investors sold 6,774,541 Epizyme, Inc shares in Q3 2022, an estimated $9.96M.
- Palo Alto Investors first reported a position in Epizyme, Inc in Q2 2015 and held it in 29 quarters.
- Palo Alto Investors's Epizyme, Inc position peaked at $151M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Palo Alto Investors's 13F filing for Q3 2022, filed 14 Nov 2022.